TRACT Therapeutics, Inc. Receives Orphan-Drug Designation for TRK-001 from the U.S. FDA
TRACT Therapeutics, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the Company
TRACT Therapeutics, Inc. Receives Orphan-Drug Designation for TRK-001 from the U.S. FDA
Phase I Clinical Trial with Ex Vivo Expanded Recipient Regulatory T Cells
TRACT Therapeutics, Inc. Launches the TRACT CryoBanking Program™
Results of Phase 1 Trial of Treg Adoptive Cell Transfer (TRACT) in Kidney Transplant Recipients
TRACT Therapeutics, Inc. Received FDA Approval for a Phase 2 Trial
American Transplant Congress June 12, 2016
TRACT Therapeutics, Inc. Completes Phase I Safety Trial
International Society for Cellular Therapy
TRACT Therapeutics, Inc. in White City News